Stay updated with breaking news from Margaret bradbury. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04,. ....
Members of the Franciscan Missionaries of St. Joseph (FMSJ) who celebrated their Jubilees and professions in Kenya have been urged to cling to Jesus Christ, and not to quit in the face of hardships. ....
ATH434 protects brain cells and improves motor function in Parkinsonian disorder Oral presentation at the American Academy of Neurology News provided by Share this article MELBOURNE, Australia , April 21, 2021 /PRNewswire/ Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ( Alterity or the Company ) today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting. The AAN conference, held this week, is the world s preeminent clinical and scientific conference in the neurology space. The presentation titled ATH434 Preserves Dopaminergic Neurons, Reduces α-synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model ....
Share this article Share this article NEW YORK, Feb. 9, 2021 /PRNewswire/ Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ( Alterity or the Company ) has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson s Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson s disease (PD) based on imaging of brain iron. The funding for US$495,000 will be used to evaluate the pharmacologic profile of ATH434 in a primate model to determine the optimal dose of ATH434 in future Parkinson s disease clinical trials. This is the second grant that Alterity has received from The Michael J. Fox Foundation to support the development of ATH434 in PD. ....